EQT Completes Final Exit From Galderma with Record $5bn Block Trade

Why It Matters

The deal showcases private‑equity’s ability to generate outsized returns in high‑growth healthcare sectors, setting a new benchmark for large‑scale block trades and influencing future PE exit strategies.

Key Takeaways

• EQT sold 34M Galderma shares for CHF4.9bn.
• Transaction marks largest sponsor‑backed block trade ever.
• EQTs total Galderma proceeds reach CHF21bn.
• Galderma revenue doubled to $5.2bn by 2025.
• Share price tripled since 2024 IPO.

Pulse Analysis

EQT’s final divestiture from Galderma illustrates how private‑equity firms can orchestrate massive liquidity events while preserving value creation. By leveraging an accelerated book‑building process and a consortium of top-tier banks, EQT secured a CHF 4.9 billion block trade that eclipses previous sponsor‑backed transactions. This execution not only delivers a record‑setting exit for the firm but also signals growing confidence among institutional investors in large‑scale secondary offerings, a trend that could reshape capital‑raising dynamics for other private‑equity‑owned companies.

Galderma’s transformation under EQT’s ownership highlights the potency of strategic focus within the dermatology market. From a $2.8 billion revenue base in 2018, the company expanded to $5.2 billion by 2025, driven by robust product launches across injectable aesthetics, skincare, and therapeutic treatments. The 2024 IPO, one of Europe’s biggest that year, saw the stock price nearly triple, reflecting strong investor appetite for innovative skin‑health portfolios. This growth trajectory underscores how targeted R&D investment and global market penetration can amplify a firm’s valuation in a niche yet rapidly expanding sector.

The broader implications for the private‑equity landscape are significant. EQT’s CHF 21 billion cumulative return from Galderma sets a new performance bar, encouraging other firms to pursue similar high‑growth, specialty‑focused acquisitions. Moreover, the successful block trade may inspire more sponsors to consider large, coordinated secondary sales as an exit route, especially in markets where public listings have already unlocked substantial upside. As healthcare continues to attract capital, the Galderma case provides a blueprint for aligning operational excellence with financial engineering to achieve record‑level outcomes.